SEELOS THERAPEUTICS INC's ticker is SEEL and the CUSIP is 81577F109. A total of 84 filers reported holding SEELOS THERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is 0.24 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $51,948 | -86.1% | 282,327 | -9.6% | 0.00% | -100.0% |
| Q2 2023 | $373,308 | +67.0% | 312,392 | -3.4% | 0.00% | 0.0% |
| Q1 2023 | $223,483 | -74.4% | 323,326 | -74.9% | 0.00% | -50.0% |
| Q4 2022 | $874,001 | -60.8% | 1,287,189 | -40.5% | 0.00% | -50.0% |
| Q3 2022 | $2,227,000 | +41.0% | 2,161,965 | -6.8% | 0.00% | +100.0% |
| Q2 2022 | $1,579,000 | -15.9% | 2,320,946 | +3.6% | 0.00% | 0.0% |
| Q1 2022 | $1,878,000 | +18.8% | 2,241,068 | +131.0% | 0.00% | +100.0% |
| Q4 2021 | $1,581,000 | +2008.0% | 969,993 | +3305.0% | 0.00% | – |
| Q2 2021 | $75,000 | – | 28,487 | +167470.6% | 0.00% | – |
| Q4 2020 | $0 | – | 17 | 0.0% | 0.00% | – |
| Q3 2020 | $0 | – | 17 | 0.0% | 0.00% | – |
| Q2 2020 | $0 | – | 17 | 0.0% | 0.00% | – |
| Q1 2020 | $0 | – | 17 | 0.0% | 0.00% | – |
| Q4 2019 | $0 | – | 17 | 0.0% | 0.00% | – |
| Q3 2019 | $0 | – | 17 | 0.0% | 0.00% | – |
| Q2 2019 | $0 | – | 17 | 0.0% | 0.00% | – |
| Q1 2019 | $0 | – | 17 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ACUTA CAPITAL PARTNERS, LLC | 2,500,000 | $4,075,000 | 1.71% |
| Connacht Asset Management LP | 498,925 | $813,000 | 0.79% |
| GENDELL JEFFREY L | 2,449,267 | $3,992,000 | 0.32% |
| MANGROVE PARTNERS IM, LLC | 2,133,436 | $3,478,000 | 0.21% |
| Uniplan Investment Counsel, Inc. | 1,550,359 | $2,527,000 | 0.14% |
| Financial Advocates Investment Management | 24,673 | $1,994,000 | 0.13% |
| Connacht Asset Management LP | 72,300 | $118,000 | 0.12% |
| Woodline Partners LP | 4,047,231 | $6,597,000 | 0.09% |
| 1492 Capital Management LLC | 108,286 | $177,000 | 0.09% |
| Ikarian Capital, LLC | 244,171 | $398,000 | 0.06% |